2 completed, 1 terminated. 3 Phase 3, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 3 | Completed 2, Terminated 1 |
| Phase 2 | 1 | Terminated 1 |
Follow MP0420: new trials by email Literature Review of MP0420 trials Research Report on MP0420
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| MP0420 for Inpatients With COVID-19 (An ACTIV-3/TICO Treatment Trial) MP0420, Placebo, Remdesivir - COVID-19 | Phase 3 | Completed | National Institute of Allergy and Infectious Diseases (NIAID) | 485 | 2021-06-11 | 2024-02-05 |
| A Dose Finding, Efficacy and Safety Study of Ensovibep (MP0420) in Ambulatory Adult Patients With Symptomatic COVID-19 ensovibep, Placebo - COVID-19 | Phase 2 / Phase 3 | Terminated | Novartis Pharmaceuticals | 407 | 2021-05-10 | 2026-01-27 |
| ACTIV-3: Therapeutics for Inpatients With COVID-19 LY3819253, Placebo, Remdesivir - Covid19 | Phase 3 | Completed | National Institute of Allergy and Infectious Diseases (NIAID) | 2753 | 2020-08-04 | 2023-08-25 |
COVID-19 (3) · Coronaviridae Infections (2) · Coronavirus Infections (2) · Nidovirales Infections (2) · RNA Virus Infections (2) · Severe Acute Respiratory Syndrome (2) · Virus Diseases (2)
National Institute of Allergy and Infectious Diseases (NIAID) (2) · Novartis Pharmaceuticals (1)
United States (3) · Denmark (2) · Greece (2) · Nigeria (2) · Poland (2) · Singapore (2) · Spain (2) · Switzerland (2) · Uganda (2) · United Kingdom (2) · Hungary (1) · India (1) · Netherlands (1) · South Africa (1)
James Neaton, Prof. (1) · Jens Lundgren, Prof. (1) · Prof. James Neaton (1) · Prof. Jens Lundgren (1)
PMID 35939810, PMID 33356051, PMID 34473343, PMID 34928698, PMID 34953520, PMID 35298440, PMID 35713300, PMID 35817072, PMID 37948759, PMID 39922466, PMID 40262279